Organon Completes Spin-Out From Merck With Five Biosimilars
Adalimumab Recently Launched In Australia And Canada
Executive Summary
With ambitions to continue to invest in its long-standing relationship with Samsung Bioepis, Organon has completed its spin-out from Merck & Co.
You may also be interested in...
Organon CEO Uncertain Over Long-Term Future Of Biosimilars Business
Organon CEO Kevin Ali has acknowledged that the long-term future for the biosimilars business is unclear, despite the firm’s biosimilars segment currently acting as a solid growth driver for the company.
Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab
Organon has agreed to pay an upfront price of $73m plus potentially a further $30m in milestone payments this year alone for the rights to Shanghai Henlius Biotech’s HLX14 denosumab and HLX11 pertuzumab biosimilar candidates outside China. The deal also offers Organon an option to negotiate with Henlius for rights to its ipilimumab biosimilar.
Pfizer Bids To Stop Samsung Bioepis’ Etanercept In Australia
Enbrel (etanercept) originator Pfizer has filed suit in Australia over the sale of Samsung Bioepis’ rival Brenzys biosimilar. It alleges that it has “suffered, and will continue to suffer, substantial loss and damage.”